Teva Pharmaceutical Industries LTD (TEVA) Financial Statements
Industry: Pharmaceutical Preparations
In fiscal 2025, Teva Pharmaceutical Industries reported revenue of $17.26B, up 4.3% from $16.54B the year before. Net income was $1.41B (a 8.2% net margin), or $1.21 per diluted share. Gross margin was 51.8% and operating margin was 12.5%. Operating activities generated $1.65B of cash, leaving $1.15B of free cash flow. At fiscal year end, Teva Pharmaceutical Industries held $40.75B in total assets against $32.83B in total liabilities, including $3.56B of cash and equivalents.
Open the full interactive Teva Pharmaceutical Industries financials → Quarterly statements, key ratios, valuation history and price charts.
Teva Pharmaceutical Industries Key Stats
| Share Price | $41.25 |
|---|---|
| Market Cap | $48.06B |
| P/E Ratio | 34.1 |
| Revenue YoY Growth | +4.3% |
| 52-Week Range | $18.95 – $41.25 |
| Shares Outstanding | 1.17 billion (basic, 2026 Q2) |
Teva Pharmaceutical Industries Income Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $16.66B | $15.88B | $14.93B | $15.85B | $16.54B | $17.26B |
| Cost of Goods Sold | $8.93B | $8.28B | $7.95B | $8.20B | $8.48B | $8.32B |
| Gross Profit | $7.73B | $7.59B | $6.97B | $7.64B | $8.06B | $8.94B |
| Operating Income | -$3.57B | $1.72B | -$2.10B | $433.0M | -$303.0M | $2.16B |
| Pre-Tax Income | -$4.41B | $658.0M | -$3.06B | -$624.0M | -$1.28B | $1.22B |
| Income Tax | -$168.0M | $211.0M | -$638.0M | -$7.0M | $676.0M | -$180.0M |
| Net Income | -$3.99B | $417.0M | -$2.35B | -$559.0M | -$1.64B | $1.41B |
| Diluted EPS | -$3.64 | $0.38 | -$2.12 | -$0.50 | -$1.45 | $1.21 |
Teva Pharmaceutical Industries Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $4.48B | $4.71B | $3.98B | $4.14B |
| Net Income | $433.0M | $481.0M | $369.0M | -$576.0M |
| Diluted EPS | $0.37 | $0.41 | $0.31 | -$0.49 |
Teva Pharmaceutical Industries Balance Sheet
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $2.18B | $2.17B | $2.80B | $3.23B | $3.30B | $3.56B |
| Current Assets | $13.01B | $12.57B | $12.05B | $12.48B | $12.55B | $13.95B |
| Total Assets | $50.64B | $47.67B | $44.01B | $43.48B | $39.33B | $40.75B |
| Current Liabilities | $13.16B | $11.03B | $11.47B | $12.25B | $12.80B | $13.46B |
| Total Long-Term Debt | $28.16B | $24.52B | $23.35B | $21.54B | $19.58B | $33.63B |
| Total Liabilities | $39.58B | $36.42B | $35.31B | $35.35B | $33.61B | $32.83B |
| Shareholders' Equity | $10.03B | $10.28B | $7.90B | $7.51B | $5.37B | $7.91B |
Teva Pharmaceutical Industries Cash Flow Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash From Operations | $1.22B | $798.0M | $1.59B | $1.37B | $1.25B | $1.65B |
| Cash From Investing | $863.0M | $1.52B | $656.0M | $968.0M | $792.0M | $737.0M |
| Cash From Financing | -$1.89B | -$2.17B | -$1.49B | -$1.91B | -$1.79B | -$2.15B |
| Free Cash Flow | $638.0M | $236.0M | $1.04B | $842.0M | $749.0M | $1.15B |
Figures from Teva Pharmaceutical Industries' 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full Teva Pharmaceutical Industries financials page for every line item.
Teva Pharmaceutical Industries Company Profile
| Ticker | TEVA |
|---|---|
| Exchange | NYSE |
| Industry | Pharmaceutical Preparations |
| Headquarters | Tel Aviv |
| Fiscal Year End | December 31 |
| SEC Filer Category | Large accelerated filer |
| SEC CIK | 0000818686 |
Frequently Asked Questions
What was Teva Pharmaceutical Industries' revenue in fiscal 2025?
Teva Pharmaceutical Industries (TEVA) reported revenue of $17.26B for fiscal 2025.
What is Teva Pharmaceutical Industries' annual revenue history?
Teva Pharmaceutical Industries' annual revenue by fiscal year: 2020: $16.66B; 2021: $15.88B; 2022: $14.93B; 2023: $15.85B; 2024: $16.54B; 2025: $17.26B.
What was Teva Pharmaceutical Industries' net income in fiscal 2025?
Teva Pharmaceutical Industries reported net income of $1.41B for fiscal 2025.
What was Teva Pharmaceutical Industries' earnings per share (EPS) in fiscal 2025?
Teva Pharmaceutical Industries' diluted EPS was $1.21 for fiscal 2025 (adjusted for any later stock splits).
How much free cash flow did Teva Pharmaceutical Industries generate in fiscal 2025?
Teva Pharmaceutical Industries generated $1.15B of free cash flow in fiscal 2025.
What was Teva Pharmaceutical Industries' revenue last quarter?
In its most recent reported quarter (2026 Q2), Teva Pharmaceutical Industries reported revenue of $4.14B.
How much debt does Teva Pharmaceutical Industries have?
Teva Pharmaceutical Industries reported $33.63B of long-term debt, including the current portion, at the end of fiscal 2025.
How many shares of Teva Pharmaceutical Industries are outstanding?
Teva Pharmaceutical Industries reported a weighted average of 1.17 billion basic shares outstanding in 2026 Q2.
What is Teva Pharmaceutical Industries' market cap?
Based on its latest closing price, Teva Pharmaceutical Industries (TEVA) has a market capitalization of about $48.06B.
When does Teva Pharmaceutical Industries' fiscal year end?
Teva Pharmaceutical Industries' fiscal year end, as registered with the SEC, is December 31.
Where is Teva Pharmaceutical Industries headquartered?
Teva Pharmaceutical Industries lists its business address in Tel Aviv in its SEC filings.